131782-50-8

Basic information

• Product Name: 3,5-DIFLUORO-2-METHOXYBENZALDEHYDE
• Synonyms: 3,5-DIFLUORO-2-METHOXYBENZALDEHYDE;3,5-Difluoro-o-anisaldehyde, 2,4-Difluoro-6-formylanisole
• CAS NO: 131782-50-8
• Molecular Formula: C₈H₆F₂O₂
• Molecular Weight: 172.13
• Mol File: 131782-50-8.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 243.9°C at 760 mmHg
• Flash Point: 98.5°C
• Appearance: /
• Density: 1.289g/cm³
• Vapor Pressure: 0.0312mmHg at 25°C
• Refractive Index: 1.506
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Sensitive: Air Sensitive
• CAS DataBase Reference: 3,5-DIFLUORO-2-METHOXYBENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-DIFLUORO-2-METHOXYBENZALDEHYDE(131782-50-8)
• EPA Substance Registry System: 3,5-DIFLUORO-2-METHOXYBENZALDEHYDE(131782-50-8)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 131782-50-8(Hazardous Substances Data)

Usage

General Description

3,5-Difluoro-2-methoxybenzaldehyde is a specialized aromatic compound, also known as an arene or aryl compound, which is typically used in the fields of medicine and pharmaceuticals due to its potential medicinal properties. It possesses a chemical formula of C8H6F2O2, showcasing two fluorine atoms, an oxygen atom, and a methoxy group (OCH3) attached to a benzene ring. As an organic compound, it generally serves as an intermediate in organic synthesis due to its high reactivity. Safety precautions are advised during its handling as its effects on human health and the environment have not been intensively studied. Its properties include being a yellow liquid and having a high boiling point due to the presence of extensive intermolecular forces.

InChI:InChI=1/C8H6F2O2/c1-12-8-5(4-11)2-6(9)3-7(8)10/h2-4H,1H3

Upstream product

• 114636-02-1 2-(trimethylsilyl)-4-methoxy-1,3-difluorobenzene 
• 452-10-8 2,4-difluoro-1-methoxybenzene 
• 367-27-1 2,4-difluorophenol 

Downstream Products

• 152434-97-4 2,6-difluoro-4-hydroxy-3-methoxybenzaldehyde 
• 152434-99-6 2,6-difluoroveratraldehyde 
• 152434-96-3 1-<(tert-butyldimethylsilyl)oxy>-3,5-difluoro-2-methoxybenzene 
• 152435-00-2 2,6-difluoro-3,4-dimethoxyphenethanolamine 
• 152434-75-8 2,6-difluoronorepinephrine 
• 1158948-04-9 2,3,4-tribromo-5-(3,5-difluoro-2-hydroxyphenyl)-1H-pyrrole 
• 1158948-10-7 2,3,4-tribromo-5-(3,5-difluoro-2-methoxyphenyl)-1H-pyrrole 
• 1198777-68-2 2-(3,5-difluoro-2-methoxyphenyl)-1H-pyrrole 
• 1198777-67-1 2-(3,5-difluoro-2-methoxyphenyl)-1-(p-tolylsulfonyl)-2,3-dihydro-1H-pyrrole 
• 1198777-64-8 N-[1-(3,5-difluoro-2-methoxyphenyl)-but-3-ynyl]-4-methylbenzene-sulfonamide 
• 1198777-60-4 N-[1-(3,5-difluoro-2-methoxyphenyl)-4-(trimethylsilyl)but-3-ynyl]-4-methylbenzenesulfonamide 
• 1198777-57-9 N-(3,5-difluoro-2-methoxybenzylidene)-4-methylbenzenesulfonamide 
• 131782-51-9 (3,5-difluoro-2-methoxy-phenyl)-methanol 
• 1002344-78-6 [(3,5-difluoro-2-methoxyphenyl)methylene]-2-methylquinolin-5-amine 

Relevant articles and documents

Naphthalenylmethoxypiperidines as renin inhibitors

The present invention relates to compound of formula (I) wherein R1, R2and R3are as defined in the description and claims and pharmaceutically acceptable salts thereof. The compounds are useful for treating diseases associated with restenosis, glaucoma, cardiac infarct, high blood pressure and end organ damage, e.g. cardiac insufficiency and kidney insufficiency.

Syntheses of 2,5- and 2,6-Difluoronorepinephrine, 2,5-Difluoroepinephrine, and 2,6-Difluorophenylephrine: Effect of Disubstitution with Fluorine on Adrenergic Activity

Synthetic routes to difluorinated analogs of the adrenergic agonists, norepinephrine (NE), epinephrine (E), and phenylephrine (PE) have been developed.The syntheses were based on elaboration of the ethanolamine side chains from the appropriately polyfunctionalized benzaldehydes.The benzaldehydes were prepared from precursor difluorinated benzenes by sequential regioselective lithiations and reaction with electrophiles to introduce hydroxyl and carboxaldehyde functionalities.Binding and functional assay data demonstrate that the 2,6-difluorinated analogs are relatively inactive at both α- and β-adrenergic receptors.These results are consistent with earlier observations that 2-fluoro substitution of adrenergic agonists decreases α-adrenergic activity whereas 6-fluoro substitution decreases β-adrenergic activity.